The MenB (meningitis B) vaccine gives strong protection at first, but immunity wanes over a few years , and how long it “lasts” depends on age, product, and dose schedule.

Quick Scoop

  • In infants on the UK schedule (2 doses + booster at 12 months), protection is estimated to last:
    • About 18 months after the 2‑dose primary course.
* About **36 months (3 years)** after the 12‑month booster.
  • In toddlers, children and teens, protective antibodies often stay well above pre‑vaccine levels for 2–4+ years , but they drop gradually over time.
  • Because disease is rare but fast and severe, many programs aim for good protection during peak‑risk years (infancy and later teen/young adult years), not lifelong immunity.
  • You can’t assume you’re still fully protected years later without considering:
    • Your age when vaccinated
    • Which MenB vaccine you had (e.g., 4CMenB/Bexsero vs others)
    • How many doses and whether you had a booster

How Long Does It Last (In Practice)?

Infants (e.g., UK baby schedule – Bexsero/4CMenB)

  • Expert UK committee estimates:
    • Most plausible duration of protection:
      • ~18 months after a 2‑dose infant course.
  * **~36 months** after the extra booster at 12 months.
  • Studies show antibody levels fall over time but many children still have protective levels against at least one vaccine component 2–3 years after the final dose.

Toddlers and young children

  • After 2–3 doses in toddlerhood, many children still have protective antibodies against several MenB components 2–3 years later , but levels are clearly lower than soon after vaccination.
  • Some components (like NadA) stay high in a large majority, while others (like certain PorA and fHbp responses) drop more quickly.

Teens and young adults

  • In adolescents, antibodies remain higher than before vaccination for several years; one study found meaningful levels still present up to 7.5 years , though reduced compared to soon after the shots.
  • Real‑world use of MenB vaccines in outbreaks and on campuses shows they’re most protective in the first few years after completion of the series, which is why they’re often given shortly before or during high‑risk periods (e.g., entering university halls).

Simple table: protection over time (approximate)

[3] [4][5][1] [9][1]
Group Typical schedule Protection window most strongly supported by data
Infants 2 doses in infancy + booster at 12 months (e.g., UK) Strong protection through early toddler years; estimates ~18 months after primary series, ~36 months after booster.
Toddlers/children 2–3 doses in 1–4 year olds Antibodies still often protective 2–3 years later, but clearly waning and variable by strain.
Teens/young adults 2 doses (often for higher‑risk groups or universities) Good protection in the first few years; some antibody responses detectable for 4–7+ years, but lower than peak.

Why you still hear about boosters and outbreaks

  • MenB immunity is not lifelong , and antibodies fall at different speeds for different strains.
  • Expert groups (like the UK JCVI) set schedules to cover highest‑risk ages , then may add boosters if evidence and outbreaks suggest they’re needed.
  • Because disease is rare, measuring exact “years of protection” is tricky; most estimates are based on lab antibody levels rather than counting cases.

What this means for you personally

If you or your child had the meningitis B vaccine and you’re wondering “am I still protected?”:

  1. Check:
    • Age now and age at vaccination
    • How many doses and any boosters
    • Which country’s schedule you followed
  2. Ask your doctor or nurse whether:
    • You’re still within the strongest protection window , or
    • You fall into a higher‑risk group where extra doses or other meningitis vaccines (like MenACWY) are recommended.

For urgent worries (e.g., known contact with a meningitis case, or symptoms like fever, rash, neck stiffness, confusion, severe headache), seek medical care immediately , regardless of vaccine history. Bottom note: Information gathered from public forums or data available on the internet and portrayed here.